AGB101 is the first investigational therapeutic that targets the reduction of hippocampal overactivity. The study evaluates both Primary and Secondary Endpoints to measure cognitive and functional efficacy. Secondary imaging endpoints will include measures of neurodegeneration. BALTIMORE, MD (January 17, 2019)…
– NIH awards an expected $16 million to support Phase 3 pivotal clinical trial of AGB-101, a once-a-day treatment to slow progression in Mild Cognitive Impairment due to Alzheimer’s disease. – NIH awards follow on funding from the Blueprint Neurotherapeutics…
Gallagher highlights the groundbreaking clinical trial, HOPE4MCI, which could slow progression from Mild Cognitive Impairment to Alzheimer’s dementia LOS ANGELES, April 30, 2018 — Today, AgeneBio Founder Dr. Michela Gallagher participated in a panel discussion at the Milken Global Conference Alzheimer’s Disease: Rewriting the Playbook.…
Emerging Therapeutics Focus on Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief…
Focus on Research Targeting Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief…
Enrollment of First Patients Expected in Q1 2018 Baltimore, MD, September 19, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced it has been awarded a grant from the National Institute on Aging…
Grant to support novel GABAA program targeting hippocampal overactivity that leads to neurodegeneration and cognitive decline in Alzheimer’s disease patients Baltimore, MD, September 13, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced…
Founder and CSO Michela Gallagher, PhD co-chaired a featured symposium, “The Two-Way Street Linking B-Amyloid, Tau and Neural Activity” and presented “Age-Related Network Dysfunction: Contributions of Neural Activity to Risk for Late Onset Alzheimer’s Disease.” Details available here.
Novel GABAA program targets hippocampal overactivity that leads to neurodegeneration and cognitive decline in Alzheimer’s disease patients Baltimore, MD, June 28, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the Company…
Baltimore, MD, February 17, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at the Neuroscience BioPartnering & Investment Forum. CEO Jerry McLaughlin will present a overview of AgeneBio‘s work in…
